AstraZeneca received FDA approval for Seroquel XR for adjunctive treatment of Major Depressive Disorder (MDD) on Friday. The announcement is an acknowledgement of how many physicians have been using the drug off-label for some time.
This won’t have major implications for product sales, but does help AZ in promoting the product in a heavily congested class.
This won’t have major implications for product sales, but does help AZ in promoting the product in a heavily congested class.